About Blood Immunology & Cellular Therapy

Blood Immunology & Cellular Therapy provides an international platform for publishing original research in basic, translational, and clinical investigations related to cellular and non-cellular immunotherapies for neoplastic conditions and the underlying immunology.

The scope includes non-cellular therapies like vaccinations, monoclonal antibodies (e.g., bispecific antibodies and BiTEs), antibody-drug conjugates, and immune checkpoint inhibitors. It also covers cellular therapies, such as CAR-T cells, TCR-engineered T-cells, CAR-NK cells, NK cells, T-Regs and mesenchymal stromal cells (MSC). In addition, gene therapies, including vector design, gene editing (CRISPR-Cas9, base editing), and ex-vivo/in-vivo approaches for congenital conditions like primary immune deficiencies, hemoglobinopathies, metabolic disorders and hemophilia, are featured.

Selected topics related to the immunological aspects of allogeneic-SCT, including graft rejection, graft-versus-leukemia effect, donor lymphocyte infusion (DLI) and graft-versus-host disease may also be included but general allogeneic stem cell transplantation (SCT) is not within the scope of Blood ICT.

The use of cellular and immunotherapies for the treatment of non-malignant immunologic diseases will be considered but general immunology and non-neoplastic immunologic conditions are not within scope.

Submissions related to regulatory and manufacturing issues are within scope.